The American Journal of Medicine
Volume 120, Issue 9, Supplement 1 , Pages S25-S31 , September 2007

What Is the Potential Role of Cannabinoid-1 Receptor Blockade in Glucose and Lipid Management?

  • Michael D. Jensen, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Michael D. Jensen, MD, Endocrine Research Unit, Division of Endocrinology, Diabetes, Metabolism, & Nutrition, 5-194 Joseph, Mayo Clinic, Rochester, Minnesota 55905.

References 

  1. Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?. Am J Med. 2007;120(suppl 8B):S18–S24
  2. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389–1397
  3. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. [letter] Nature. 2001;410:822–825
  4. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423–431
  5. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol. 2003;284:R345–R353
  6. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 2005;19:1567–1569
  7. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003;63:908–914
  8. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep ob/Lep ob mice. Int J Obes (Lond). 2005;29:183–187
  9. Després JP, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–2134
  10. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America, a randomized controlled trial. JAMA. 2006;295:761–775
  11. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet. 2006;368:1660–1672
  12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  13. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298–1305
  14. Pi-Sunyer X, Després J-P, Scheen A, Van Gaal L. Improvement of metabolic parameters with rimonabant beyond the effect attributable to weight loss alone: pooled one-year data from the RIO (Rimonabant In Obesity and Related Metabolic Disorder) program. J Am Coll Cardiol. 2006;47(suppl 1):362A;Abstract 849–3

PII: S0002-9343(07)00549-9

doi: 10.1016/j.amjmed.2007.06.011

The American Journal of Medicine
Volume 120, Issue 9, Supplement 1 , Pages S25-S31 , September 2007

Article Tools

* Image Usage & Resolution